Compare FFWM & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFWM | LYEL |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | 485 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 556.1M |
| IPO Year | 2014 | 2021 |
| Metric | FFWM | LYEL |
|---|---|---|
| Price | $5.90 | $16.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $6.17 | ★ $30.60 |
| AVG Volume (30 Days) | ★ 4.3M | 52.0K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,373,000.00 | $36,000.00 |
| Revenue This Year | $56.34 | N/A |
| Revenue Next Year | $10.68 | $8,712.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.59 | $0.40 |
| 52 Week High | $6.72 | $45.00 |
| Indicator | FFWM | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 26.21 |
| Support Level | $5.44 | $15.82 |
| Resistance Level | $5.97 | $19.02 |
| Average True Range (ATR) | 0.19 | 1.27 |
| MACD | 0.03 | -0.43 |
| Stochastic Oscillator | 80.63 | 12.55 |
First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.